NASDAQ:RGLS

Regulus Therapeutics Earnings Date, Estimates, & History

$0.23

+0.02 (+9.70%)

(As of 05/20/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.20
▼
$0.24
50-Day Range: $0.16
▼
$0.34
52-Week Range: $0.16
▼
$1.48

Volume: 1.44 million shs
Average Volume: 4.26 million shs
Market Capitalization: $33.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 2.21

Upcoming Earnings Date: Aug. 9Estimated
Actual EPS (May. 12): -$0.05
Consensus EPS (May. 12): -$0.05
Last Year's Q2 EPS (5/13/2021): -$0.08

Read Call Transcript

Listen to Call

Earnings Per Share Revenue

Regulus Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Regulus Therapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regulus Therapeutics (NASDAQ:RGLS) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2022	1	($0.09)	($0.09)	($0.09)
Q2 2022	1	($0.09)	($0.09)	($0.09)
Q3 2022	1	($0.10)	($0.10)	($0.10)
Q4 2022	1	($0.10)	($0.10)	($0.10)
FY 2022	4	($0.38)	($0.38)	($0.38)

RGLS Earnings Information

Regulus Therapeutics last announced its quarterly earnings data on May 12th, 2022. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). Regulus Therapeutics has generated ($0.30) earnings per share over the last year (($0.30) diluted earnings per share). Earnings for Regulus Therapeutics are expected to grow in the coming year, from ($0.22) to ($0.19) per share. Regulus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off prior year's report dates.

Regulus Therapeutics (NASDAQ:RGLS) Earnings History by Quarter

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
8/9/2022 (Estimated)
5/12/2022	3/31/2022	($0.05)	($0.05)
3/10/2022	Q4 2021	($0.05)	($0.07)	($0.02)	($0.07)
11/10/2021	9/30/2021	($0.08)	($0.10)	($0.02)	($0.10)
8/10/2021	6/30/2021	($0.08)	($0.08)		($0.08)
5/13/2021	3/31/2021	($0.09)	($0.08)	+$0.01	($0.08)
3/8/2021	12/31/2020	($0.14)	($0.03)	+$0.11	($0.03)	$0.02 million	$5.00 million
11/5/2020	9/30/2020	($0.21)	($0.04)	+$0.17	($0.04)	$0.51 million	$5.00 million
8/13/2020	Q2 2020	($0.1070)	($0.233105)	($0.126105)	($0.23)
5/14/2020	3/31/2020	($0.12)	($0.25)	($0.13)	($0.25)	$10.00 million	$6.00 million
3/12/2020	12/31/2019	($0.24)	($0.23)	+$0.01	($0.23)	$0.02 million	$0.02 million

11/12/2019	Q3	($0.2630)	($0.26)	+$0.0030	($0.26)	$0.02 million	$0.02 million
8/8/2019	Q2 2019	($0.5430)	($0.30)	+$0.2430	($0.30)	$2.50 million	$0.02 million
5/9/2019	Q1	($1.15)	($0.31)	+$0.84	($0.31)	$0.02 million	$6.78 million
3/18/2019	12/31/2018	($0.92)	($0.98)	($0.06)	($0.98)	$7.01 million	$0.02 million
11/8/2018	Q3	($1.2520)	($1.18)	+$0.0720	($1.18)	$0.02 million	$0.02 million
8/9/2018	Q2 2018	($0.1550)	($0.1330)	+$0.0220	($0.13)	$0.02 million	$0.02 million
5/10/2018	Q1 2018	($0.15)	($0.15)		($0.15)	$0.02 million	$0.02 million
3/7/2018	Q4 2017	($0.17)	($0.14)	+$0.03	($0.14)	$0.02 million	$0.02 million
11/7/2017	Q3 2017	($0.18)	($0.18)		($0.18)	$0.02 million	$0.02 million
8/1/2017	Q2 2017	($0.31)	($0.4060)	($0.0960)	($0.41)	$0.02 million	$0.02 million
5/4/2017	Q1 2017	($0.33)	($0.38)	($0.05)	($0.38)	$0.02 million	$0.02 million
3/2/2017	Q4 2016	($4.32)	($4.56)	($0.24)	($4.56)	$0.20 million	$0.02 million
11/1/2016	Q3 2016	($0.39)	($0.37)	+$0.02	($0.37)	$0.50 million	$0.20 million
8/2/2016	Q2 2016	($4.68)	($4.80)	($0.12)	($4.80)	$0.50 million	$0.48 million
5/2/2016	Q1 2016	($3.96)	($4.80)	($0.84)	($4.80)	$2.25 million	$0.49 million
2/22/2016	Q4 2015	($3.12)	($1.68)	+$1.44	($1.68)	$5.09 million	$10.90 million
11/5/2015	Q3 2015	($4.80)	($3.00)	+$1.80	($3.00)	$3.57 million	$1.87 million
8/4/2015	Q2 2015	($3.72)	($4.92)	($1.20)	($4.92)	$2.40 million	$3.80 million
5/7/2015	Q1 2015	($3.12)	($3.00)	+$0.12	($2.52)	$3.38 million	$4.20 million
2/18/2015	Q4 2014	($3.00)	($2.40)	+$0.60	$0.84	$2.24 million	$4.22 million
11/5/2014	Q3 2014	($2.52)	($3.60)	($1.08)	($4.08)	$2.76 million	$1.08 million
8/6/2014	Q2 2014	($2.64)	($3.72)	($1.08)	($3.96)	$3.20 million	$0.74 million
5/8/2014	Q1 2014	($1.92)	($3.00)	($1.08)	($2.40)	$3.80 million	$1.63 million
2/27/2014	Q4 2013	($1.68)	($1.80)	($0.12)	($2.28)	$3.69 million	$5.45 million
11/13/2013	Q3 2013	($0.16)	($0.07)	+$0.09	($0.07)	$3.56 million	$6.12 million
8/13/2013	Q2 2013	($1.80)	($1.44)	+$0.36	($0.48)	$3.44 million	$4.80 million
5/14/2013	Q1 2013	($0.09)	($0.20)	($0.11)	($0.20)	$2.96 million	$3.24 million
2/20/2013	Q412	($0.08)	($0.22)	($0.14)		$3.50 million	$3.24 million
11/19/2012	Q312		($15.98)	($15.98)		$3.81 million	$2.80 million

(Earnings results data provided by Zacks Investment Research)

Regulus Therapeutics (NASDAQ:RGLS) Earnings Frequently Asked Questions

When is Regulus Therapeutics's earnings date?: Regulus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off last year's report dates. Learn more on RGLS's earnings history.
Did Regulus Therapeutics beat their earnings estimates last quarter?: In the previous quarter, Regulus Therapeutics (NASDAQ:RGLS) reported ($0.05) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.05). Learn more on analysts' earnings estimate vs. RGLS's actual earnings.
How can I listen to Regulus Therapeutics's earnings conference call?: The conference call for Regulus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call
How can I read Regulus Therapeutics's conference call transcript?: The conference call transcript for Regulus Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Regulus Therapeutics generate each year?: Regulus Therapeutics (NASDAQ:RGLS) has a recorded annual revenue of $10.01 million.
How much profit does Regulus Therapeutics generate each year?: Regulus Therapeutics (NASDAQ:RGLS) has a recorded net income of -$27.81 million. RGLS has generated -$0.30 earnings per share over the last four quarters.
What is Regulus Therapeutics's EPS forecast for next year?: Regulus Therapeutics's earnings are expected to grow from ($0.22) per share to ($0.19) per share in the next year.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources